Biotech firm leading the Alcohol Use Disorder (AUD) treatment Awakn Life Sciences Corp. (OTCQB: AWKNF) has announced its financial outcomes and business highlights for the three months ended July 31, 2022.
During the period, numbers reflected:
Total revenue of $255.719 through its London, Bristol and Oslo clinics, compared to zero in the same period of 2021 (when the facilities weren’t yet open), and a 34% increase of total $190,473 proceeds of the three-month period ended April 30, 2022.
Total cash of $362.528
Closing of private placement with 1,880,454 units issued at $0.41 each raised a total $778.169 in gross proceeds
As for business updates, Awakn’s Phase III trial recently received approx. …